Last reviewed · How we verify

NCT03939650

Diagnosis Assessment With Diaana #3

Withdrawn NA Last updated 23 September 2021
What this trial tests

NA trial testing Diaana in Decision Making. Withdrawn.

Timeline
31 January 2020
Primary endpoint
31 January 2020
31 January 2020

Quick facts

Lead sponsorAdrien Schwitzguebel
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Start date31 January 2020
Primary completion31 January 2020
Estimated completion31 January 2020
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Adrien Schwitzguebel

Who can join

Adults 16 to 65, any sex, with Decision Making or Computer-assisted. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single-center, unblinded, 2:1 parallel pseudo-randomized efficacy trial. In the intervention group only, resident physicians will be assisted by the automated medical history-taking device "Diaana" during their consultations in outpatient ambulatory unit of the Geneva University Hospital. In both groups, the differential diagnosis of the resident physician will be compared to the gold-standard diagnosis of the senior physician.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Diaana

Trials testing the same drug.

Other recruiting trials for Decision Making

Currently open trials in the same condition.

Other Adrien Schwitzguebel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing